Pacritinib citrate

(Vonjo®)

Vonjo®

Drug updated on 11/16/2023

Dosage FormCapsule (oral; 100 mg)
Drug ClassKinase inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × (10)^9/L.

Product Monograph / Prescribing Information

Document TitleYearSource
Vonjo (pacritinib) Prescribing Information.2023CTI BioPharma Corp., Seattle WA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines

Document TitleYearSource
Myeloproliferative neoplasms, version 3.2022, nccn clinical practice guidelines in oncology.2022National Comprehensive Cancer Network